3. As ot June 2 what IS value ot the synergies Hoche cipates trom a merger with Genentech? Assess the value of synergies per share of Genentech. Please use a 9% weighted average cost of capital in 3731_1r analysis. Synergies are given in an exhibit. 4. Based on DCF valuation techniques, what range of values is reasonable for Genentech as a stand-alone company in June 2008? Please exclude synergies from yur valuation and use a 9% weighted average cost of capital. You can assume that as of the end of June 2008, Genentech held approximately S7 billion in cash, which included investments and securities that were not needed in its daily operations. (Note: Exhibit 10 is a good starting point for this analysis.) 5. What does the analysis of comparable companies (Exhibits 12, 13, and 14) indicate about Genentech's value within the range established in question 4?